Vinorelbine
- Generic Name
- Vinorelbine
- Drug Type
- Small Molecule
- Chemical Formula
- C45H54N4O8
- CAS Number
- 71486-22-1
- Unique Ingredient Identifier
- Q6C979R91Y
- Background
Vinorelbine is an anti-mitotic chemotherapy drug that is used in the treatment of several types of malignancies, including breast cancer and non-small cell lung cancer (NSCLC) . It was initially approved in the USA in 1990's for the treatment of NSCLC .
It is a third-generation vinca alkaloid. The introduction of third-generation drugs (vinorelbine, gemcitabine, taxanes) in platinum combination improved survival of patients with advanced NSCLC, with very similar results from the various drugs. Treatment toxicities are considerable in the combination treatment setting .
A study was done on the clearance rate of vinorelbine on individuals with various single polymorphonuclear mutations. It was found that there was 4.3-fold variation in vinorelbine clearance across the cohort, suggesting a strong influence of genetics on the clearance of this drug .
- Indication
Vinorelbine tartrate is indicated for adults in the treatment of advanced non-small cell lung cancer (NSCLC), as a single therapy or in combination with other chemotherapeutic drugs .
Used in relapsed or refractory Hodgkin lymphoma, in combination with other chemotherapy agents .
For the treatment of desmoid tumor or aggressive fibromatosis, in combination with methotrexate .
For the treatment of recurrent or metastatic squamous cell head and neck cancer .
For the treatment of recurrent ovarian cancer .
For the treatment of metastatic breast cancer, in patients previously treated with anthracyline and/or taxane therapy .
For the treatment of HER2-positive, trastuzumab-resistant, advanced breast cancer in patients previously treated with a taxane, in combination with trastuzumab and everolimus .
- Associated Conditions
- Locally Advanced Non-Small Cell Lung Cancer, Metastatic Breast Cancer, Metastatic Cervical Cancer, Metastatic Non-Small Cell Lung Cancer, Recurrent Cervical Cancer, Soft Tissue Sarcoma
A Study of TQB2930 for Injection Monotherapy or Combination Therapy in Patients With Recurrent/Metastatic Breast Cancer
- Conditions
- Recurrent Breast CancerMetastatic Breast CancerAdvanced Malignancies
- Interventions
- First Posted Date
- 2024-01-11
- Last Posted Date
- 2024-03-12
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 154
- Registration Number
- NCT06202261
- Locations
- 🇨🇳
Affiliated Cancer Hospital of Chongqing University, Chongqing, Chongqing, China
🇨🇳Affiliated cancer hospital of harbin medical university, Harbin, Heilongjiang, China
Efficacy and Safety of Paclitaxel Polymeric Micelles for Injection in the Treatment of Metastatic Breast Cancer
- Conditions
- Metastatic Breast Cancer (MBC)
- Interventions
- First Posted Date
- 2023-11-22
- Last Posted Date
- 2024-11-28
- Lead Sponsor
- Shanghai Yizhong Pharmaceutical Co., Ltd.
- Target Recruit Count
- 168
- Registration Number
- NCT06143553
- Locations
- 🇨🇳
Jiangsu province Hospital, Nanjing, Jiangsu, China
🇨🇳Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Trotabresib in Combination With Vinorelbine and Radiation Therapy for the Treatment of HER2+ Breast Cancer With Central Nervous System or Leptomeningeal Metastasis
- Conditions
- Breast CarcinomaMetastatic Malignant Neoplasm in the LeptomeningesMetastatic Malignant Neoplasm in the Brain
- Interventions
- Procedure: Biospecimen CollectionProcedure: Computed TomographyProcedure: Magnetic Resonance ImagingRadiation: Radiation TherapyProcedure: Resection
- First Posted Date
- 2023-11-18
- Last Posted Date
- 2024-04-01
- Lead Sponsor
- Northwestern University
- Registration Number
- NCT06137651
- Locations
- 🇺🇸
Northwestern University, Chicago, Illinois, United States
Phase III Clinical Trial Comparing the Safety, Efficacy, and Immunogenicity of HS022 and Trastuzumab® in Combination With Vinorelbine Bitartrate Injection in the Treatment of HER2-positive Breast Cancer
- Conditions
- HER2-positive Breast Cancer
- Interventions
- First Posted Date
- 2023-10-30
- Last Posted Date
- 2023-10-30
- Lead Sponsor
- Zhejiang Hisun Pharmaceutical Co. Ltd.
- Target Recruit Count
- 570
- Registration Number
- NCT06107790
- Locations
- 🇨🇳
Jiangsu Province People's Hospital (First Affiliated Hospital of Nanjing Medical University), Nanjing, Jiangsu, China
Organoid-based Functional Precision Therapy for Advanced Breast Cancer
- Conditions
- HER2-negative Breast CancerAdvanced Breast Cancer
- Interventions
- Drug: Organoid-guided treatmentDrug: Anthracycline
- First Posted Date
- 2023-10-26
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- Guangdong Provincial People's Hospital
- Target Recruit Count
- 252
- Registration Number
- NCT06102824
- Locations
- 🇨🇳
Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China
Study of SKB264 for Locally Advanced, Recurrent or Metastatic HR+/HER2- Breast Cancer
- Conditions
- Metastatic Breast Cancer
- Interventions
- First Posted Date
- 2023-10-13
- Last Posted Date
- 2024-12-12
- Target Recruit Count
- 376
- Registration Number
- NCT06081959
- Locations
- 🇨🇳
Cancer Hospital Chinese Academy of Medical Science, Beijing, Beijing, China
JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2023-10-12
- Last Posted Date
- 2023-10-12
- Lead Sponsor
- Jiangsu Alphamab Biopharmaceuticals Co., Ltd
- Target Recruit Count
- 400
- Registration Number
- NCT06079983
- Locations
- 🇨🇳
Jilin Provincial Cancer Hospital, Changchun, China
🇨🇳Guangdong Provincial People's Hospital, Guangzhou, China
🇨🇳Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China
Treatment of Newly Diagnosed Rhabdomyosarcoma Using Molecular Risk Stratification and Liposomal Irinotecan Based Therapy in Children With Intermediate and High Risk Disease
- Conditions
- Rhabdomyosarcoma
- Interventions
- Procedure: Surgical ResectionProcedure: Proton beam radiation or external beam radiation or brachytherapy
- First Posted Date
- 2023-09-05
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 135
- Registration Number
- NCT06023641
- Locations
- 🇺🇸
Cook Children's Medical Center, Fort Worth, Texas, United States
🇺🇸Sanford University, Palo Alto, California, United States
🇺🇸St. Jude Children's Research Hospital, Memphis, Tennessee, United States
A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer
- Conditions
- AdolescentNeoplasmsChild
- Interventions
- First Posted Date
- 2023-08-21
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 105
- Registration Number
- NCT05999994
- Locations
- 🇺🇸
Childrens Hospital of Alabama, Birmingham, Alabama, United States
🇺🇸Children's Hospital of Colorado, Denver, Colorado, United States
🇺🇸Phoenix Children's Hospital, Phoenix, Arizona, United States
DP303c in Patients With HER2-positive Advanced Breast Cancer
- Conditions
- HER2-positive Advanced Breast Cancer
- Interventions
- First Posted Date
- 2023-06-13
- Last Posted Date
- 2023-06-13
- Lead Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
- Target Recruit Count
- 420
- Registration Number
- NCT05901935
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.